Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581410 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
NCT02581410: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT02581410 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 430 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02581410, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
Primary Outcome
Varicella Zoster Virus (VZV) gE Ab.Immunoglobulin G (IgG) was determined by Enzyme Linked Immunosorbent Assay (ELISA). Concentrations are presented as geometric mean concentrations (GMCs), expressed in milliinternational units per millilitre (mIU/mL). Geometric mean antibody concentrations were adjusted for group-matching variable.
Interventions
- BIOLOGICAL GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2015-12-15 |
| Est. Completion | 2017-08-01 |
| Phase | Phase 3 |
What the finished NCT02581410 record still lists
NCT02581410 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (44% lower).
The record links to 0 conditions, and to 1 intervention - of which GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) is the first listed.
NCT02581410 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02581410 about?
NCT02581410 is a clinical study titled "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier". The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.
What is the current status of trial NCT02581410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2015-12-15. Estimated completion is 2017-08-01.
What interventions are being tested in trial NCT02581410?
The interventions under investigation include: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02581410?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02581410's enrollment target sits among peer trials
430 877th of 2000 higher than 1,123 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI